Inflammation Modifiers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inflammation Modifiers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inflammation Modifiers Today - Breaking & Trending Today

Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPa Inhibitor BI 765063 in Advanced Solid Tumors

Published: March 9, 2022

At American Association for Cancer Research Annual Meeting 2022 New Orleans, April 8 13 Regulatory News: OSE Immunotherapeutics (Paris:OSE)(ISIN: FR0012127173; Mnemo: OSE), today announced that

Source: finanznachrichten.de

Related Topics:

United StatesNew OrleansNew Orleans Convention CenterGuillaume Van Renterghem LifesciThomas GuillotFlorence PortejoieDarren OplandNantes University HospitalAmerican Association Cancer For ResearchBoehringer IngelheimClinical Research Excluding TrialsOrleans Convention CenterAmerican Association For Cancer Research Annual MeetingLifesci CommunicationsVeloxis Pharmaceuticals IncCancer Research Annual MeetingAmerican Association CancerInflammation ModifiersTumor MicroenvironmentMonday AprExhibit Hallsd HPoster SectionBoard NumberNon Small Cell Lung CancerVeloxis Pharmaceuticals